ADAM MOGIL: Open Payments
NPI 1245345933 · SHERMAN OAKS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,225 in 83 payments from 24 companies in 2025. Trend: 2023 $1,723 · 2024 $8,026 · 2025 $2,225
Food & beverage: $2,225
| Company | Payments | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. | 14 | $306 |
| Merck Sharp & Dohme LLC | 7 | $211 |
| Dendreon Pharmaceuticals LLC | 7 | $199 |
| Janssen Biotech, Inc. | 6 | $185 |
| Astellas Pharma US Inc | 4 | $157 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $141 |
| Blue Earth Diagnostics | 4 | $114 |
| Verity Pharmaceuticals Inc. | 3 | $93 |
| Telix Pharmaceuticals | 3 | $89 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 3 | $86 |
Products named: Xtandi, PROVENGE, ERLEADA, GEMTESA, KEYTRUDA, Nubeqa, ORGOVYX, POSLUMA.
Industry payments across CA — which companies pay providers there.
